CD274 and cancer: Indeed, antagonistic antibodies, like anti-CTLA-4, are now used as therapies in several cancers and led the way for the targeting of similar immunoregulatory molecules such as programmed cell death (PD-)1 and PD ligand-1 (PDL-1).